Download this resource

Acinetobacter is an increasingly important hospital‐associated pathogen. Multidrug resistance among Acinetobacter species continues to rise, and infection with these multidrug‐resistant organisms has a profound negative impact on patient outcomes. Carbapenem resistance is frequently used by hospitals as a definition for multidrug resistance among Acinetobacter species, because it is often associated with resistance to other antibiotic classes. Increasing carbapenem resistance among Acinetobacter species in United States hospitals has been documented in recent studies by the Centers for Disease Control and Prevention. However, these reports were limited by the number of Acinetobacter isolates examined and were not based on nationally representative samples of US hospitals. Using the largest sample size to date (to our knowledge), we examined US national and regional trends in rates of imipenem resistance among clinical isolates of Acinetobacter species collected from hospital inpatients.

Marc S. Hoffmann, MD
Michael R. Eber, BSE
Ramanan Laxminarayan, PhD, MPH